The javascript used on this site for creative design effects is not supported by your browser. Please note that this will not affect access to the content on this web site.
Skip Navigation
H H S Department of Health and Human Services
Health Resources and Services Administration
Blood Cell Transplant

A-Z Index  |  Questions? 

  • Print this
  • Email this

Glossary for the U.S. Patient Survival Report

Cell Source 

Where the blood-forming cells used for transplant are collected from.

  • Bone marrow, the soft spongy tissue found inside of bones, produces blood-forming cells for the body. The bone marrow for a transplant is collected from a donor's pelvic bone during a surgical procedure in a hospital.
  • Peripheral blood stem cells (PBSC) are found circulating in the bloodstream. Normally, the bone marrow releases a small number of blood-forming cells into the bloodstream. A donor receives injections of a medication that increases the number of blood-forming cells in the blood. Then, the donor's blood is collected in a non-surgical procedure done in an outpatient clinic.
  • Umbilical cord blood contains a large number of blood-forming cells. Cord blood is collected from the umbilical cord and placenta in a hospital after a baby is born.Disease Status 

Disease Status 

A measure of how the disease responded to treatment before the patient received a bone marrow or umbilical cord blood transplant. The disease status can help predict the likelihood of a better or worse survival outcome after transplantation.
In these reports, disease status is included only for leukemias, lymphomas and multiple myeloma.

Leukemia Disease Statuses

For chronic myelogenous leukemia (CML):

  • 1st chronic phase—Patients have low level clinical evidence of leukemia with less than 10% blast cells in the blood or bone marrow. Includes patients who are undergoing initial treatment for CML who have not progressed to more advanced disease.
  • 2nd or subsequent chronic phase or accelerated phase—Patients with low level of clinical evidence of leukemia with less than 10% blast cells in blood or marrow after being treated for more progressive disease or more advanced disease characterized as 10-19% blast cells in blood or marrow (accelerated phase).
  • Blast phase—Patients with more advanced disease with 20% or greater blasts found in the blood or marrow.

For acute myleogenous leukemia (AML) or acute lymphoblastic leukemia (ALL):

  • 1st remission—The disease responded well to treatment. There is no clinical evidence of leukemia.
  • 2nd or subsequent remission—The disease recurred after responding well to initial treatment; the disease recurred after achieving a clinical remission one or more times. After further treatment, there is no clinical evidence of leukemia.
  • Not in remission—The disease is not responding to treatment. There is still some evidence of leukemia.

Lymphoma Disease Statuses

  • 1st remission—The disease responded well to treatment. There is no clinical evidence of lymphoma.
  • 2nd or subsequent remission—The disease recurred after responding well to initial treatment; the disease recurred after achieving a clinical remission one or more times. After further treatment, there is no clinical evidence of lymphoma
  • Partial Response—The disease has responded reasonably well to treatment (>50% reduction in disease), but there is some disease remaining.
  • Active Disease (Not in remission)—The disease is not responding to treatment. There is still evidence of lymphoma.


Multiple Myeloma Disease Statuses

  • Partial response or better, transplanted after 12 months of diagnosis—The disease has responded reasonably well to treatment (>50% reduction in disease), but there is some disease remaining. The patient was transplanted more than a year after being diagnosed.
  • Partial response or better, transplanted within 12 months of diagnosis—The disease has responded reasonably well to treatment (>50% reduction in disease), but there is some disease remaining. The patient was transplanted less than a year after being diagnosed.
  • Stable/progressive disease or relapse, transplanted after 12 months of diagnosis—The patient’s disease has either not responded to therapy with at least a 50% reduction, or has progressed or relapsed despite treatment. There is active disease that is either stable or worsening. The patient was transplanted more than a year after being diagnosed.
  • Stable/progressive disease or relapse, transplanted within 12 months of diagnosis—The disease has not responded to therapy but has not progressed or there is active disease that is worsening. The patient was transplanted less than a year after being diagnosed.

Donor Type 

Biological relationship between the patient and the donor who provided the blood-forming cells.

  • Autologous—The patient's own cells were collected, stored and infused back into the patient.
  • Allogeneic—Another person donated bone marrow, peripheral blood, or an umbilical cord blood unit. These cells match the patient’s human leukocyte antigen (HLA) type. Specific allogeneic types include:
    • HLA-identical sibling—The brother or sister who donated cells is the patient's biological sibling who matches the patient’s HLA type.
    • HLA-identical twin – The brother or sister who donated cells is the patient’s monozygotic twin who shares the patient’s DNA.
    • Other related donor—The family member who donated cells is related biologically to the patient and is not included in the HLA-matched sibling or identical twin category. The donor might have variable degrees of mismatch to the patient.
    • Unrelated—The person who donated cells is not biologically related to the patient.

Human Leukocyte Antigen (HLA)

Proteins on cells that make each person's tissue type, which varies from person to person.

HLA typing is used to match patients and donors for a bone marrow or umbilical cord blood transplant. A person's HLA type is identified by testing a blood sample or swab of cheek cells.

95% Confidence Interval 

A range of numbers that represents the statistical certainty of the survival probability estimate, based on the data reported.

For example, a 95% confidence interval of 65 - 75% means there is 95% certainty that the survival probability estimate is between 65% and 75%.

Number of Patients Evaluated 

Number of patients for whom medical information was analyzed at 100 days after their bone marrow or umbilical cord blood transplant and was voluntarily reported to the Center for International Blood and Marrow Transplant Research® (CIBMTR).

Patient Age 

Age of a patient at the time of a bone marrow or umbilical cord blood transplant. These reports provide the age in 10-year intervals.

“Unknown” means the age was not reported.

Patient Gender 

The sex of a patient: male or female.

“Unknown” means the gender was not reported.

Patient Race 

Race or ethnicity of a patient. These reports have only two categories:

  • White, for Caucasian (non-Hispanic).
  • Non-white, for all other races and ethnicities.

Survival Probability Estimate 

The best estimate of the chance that a person will be alive at a specified time after transplant. This estimate is based on the data reported. View an example.

Learning About Statistics
Learning About Statistics